<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32242755</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1103</StartPage><EndPage>1110</EndPage><MedlinePgn>1103-1110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14656566.2020.1746270</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">To date, riluzole and edaravone are the only two drugs that have successfully passed clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS). Unfortunately, both drugs exhibit very modest effects. Most other drugs have failed at phase III to show significant effects in phase III when tested in larger cohorts. This pattern necessitates improvements in the approach to ALS pharmacotherapy.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">The authors discuss the two approved drugs, as well as several examples of drug candidates whose clinical trials did not demonstrate efficacy in phase III. Post-hoc analyses reveal that future clinical trials should include disease-staging procedures, longer-term trials to correctly assess survival, genetic studies of participants to aid in stratification, and more similarity between the protocols on preclinical models and clinical trials. Finally, they discuss the trials in process that demonstrate some of these suggestions and improvements.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">The approval of riluzole and edaravone was essentially a desperate attempt to provide urgent pharmacotherapy to the ALS community. To evolve toward more efficient therapies, we must conduct clinical trials with optimal stratification based on rapid/slow progressors and cognitive decline. Pharmaco-metabolomics should allow for the identification of biomarkers that are adapted for a given drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, INSERM , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanznaster</LastName><ForeName>D</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5911-3120</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, INSERM , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, INSERM , Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU De Tours, Service de Biochimie et Biologie Mol&#xe9;culaire , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Cr</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, INSERM , Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU De Tours, Service de Biochimie et Biologie Mol&#xe9;culaire , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakkouche</LastName><ForeName>Se</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, INSERM , Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU De Tours, Service de Biochimie et Biologie Mol&#xe9;culaire , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBRAIN, Universit&#xe9; de Tours, INSERM , Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie , Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CHU Limoges, Service de Neurologie, Centre Expert ALS , Limoges, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">clinical staging</Keyword><Keyword MajorTopicYN="N">dexpramipexole</Keyword><Keyword MajorTopicYN="N">edaravone</Keyword><Keyword MajorTopicYN="N">personalized medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32242755</ArticleId><ArticleId IdType="doi">10.1080/14656566.2020.1746270</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>